



# UKALL14 Christmas Newsletter 2019

A randomised trial for adults with newly diagnosed acute lymphoblastic leukaemia



With Christmas fast approaching, the UKALL14 team would like to wish you a Merry Christmas. As well as lots of presents and Christmas spirit, the festive period also brings about a few changes and updates to the UKALL14 trial which will be summarised in this newsletter.

If there are any questions, please feel free to contact a member of the UKALL14 team at [ctc.ukall14@ucl.ac.uk](mailto:ctc.ukall14@ucl.ac.uk)


Warm Christmas Wishes - UKALL14 CTC Team

## Patient registration over the Christmas period

The UCL CTC and the MRD lab will be closed from 5pm on 20th December 2019 to 9am 2nd January 2019. UCL CTC will be open on 27th December 2019 from 10am to 4pm with limited cover to process urgent registrations only. The MRD lab will not be open on this date and samples should not be sent.

During this period, the UKALL14 trial will not be open to registration (except for 27th December 2019). We ask registrations be done prior to the 20th December 2019 if possible. Any MRD samples must be sent so they are received at the lab by midday on the 20th December 2019. Any samples taken after this date should be refrigerated until shipment.

UCL CTC Christmas Opening Times				
Monday	Tuesday	Wednesday	Thursday	Friday
16 <sup>th</sup> December Normal Operation 09:00-17:00	17 <sup>th</sup> December Normal Operation 09:00-17:00	18 <sup>th</sup> December Normal Operation 09:00-17:00	19 <sup>th</sup> December Normal Operation 09:00-17:00	20 <sup>th</sup> December Normal Operation 09:00-17:00
23 <sup>rd</sup> December CLOSED	24 <sup>th</sup> December CLOSED	25 <sup>th</sup> December CLOSED	26 <sup>th</sup> December CLOSED	27 <sup>th</sup> December Open - limited cover 10:00-16:00
30 <sup>th</sup> December CLOSED	31 <sup>st</sup> December CLOSED	1 <sup>st</sup> January CLOSED	2 <sup>nd</sup> January Normal Operation 09:00-17:00	3 <sup>rd</sup> January Normal Operation 09:00-17:00



## UKALL 14 at the 61st American Society of Haematology meeting.

UKALL 14 had excellent representation at ASH this year with two talks and two poster presentations.

Adele Fielding presented the first analysis of the B-cell randomisation which showed a non-significant benefit in EFS with the addition of rituximab. The French GRAALL trial previously reported a significant benefit in EFS with the addition of 16-18 doses of rituximab in Philadelphia negative, CD20+ patients. In UKALL14, we have seen no evidence of a different treatment effect in patients with low CD20 or Philadelphia positivity so we hypothesise that the GRAALL trial results may be applicable to all patient groups and that 16-18 doses may be more effective than the 4 used in UKALL 14.

Anthony Moorman also presented data on the prognostic impact of chromosomal abnormalities and copy number alterations, giving a suggestion for a new genetic risk stratification which may be taken forward into the next trial.

The two posters also looked at genetic data from UKALL 14; one with some initial whole genome results and the second looking at the genetic characteristics of older adults in UKALL 14 and UKALL 60+.

Abstracts from ASH can be found [here](#).

## Registration only sub-study

The registration only sub-study is still open for both B-cell and T cell patients. We currently have 135 patients registered which includes 117 B-cell patients and 18 T-cell patients. Details of the eligibility criteria and registration of potential patients can be found in appendix 1 of protocol v12. Some key points relating to the registration only sub-study:

- Registration only patients do not receive IMP. Their treatment is decided by the treating clinician.
- Blood tests and samples must be taken before any steroids are given.
- Patients must be registered on the trial before any ALL treatment is given.
- MRD samples must still be sent to the central MRD lab
- Safety data does not need be reported for registration only patients.
- If a patient needs to start chemotherapy urgently, please let us know so we can prioritise urgent registrations.

### IMP Reconciliation

As all patients have completed IMP treatment for the trial, we are now undergoing IMP reconciliation. If your site has any outstanding IMP awaiting destruction, please get in touch with a member of the UKALL14 team.

In order to authorise destruction, we would require drug balance logs and patient accountability logs. Once destroyed, we require confirmation through destruction logs and updated balance logs.

### Data Chase

Requests for data had been sent out in October 2019 with a scheduled return date in November 2019. Thank you for your prompt replies. We still have some data outstanding and would like to remind any sites who have not had a chance to return data yet to send in responses by 30th January 2020.

As we are approaching the point of analysis for publication, it is important that we receive any outstanding data.

### Updated Contact List

Since the last newsletter we have had some changes to the UKALL14 trial team. We have a new Trial Coordinator and a new Data Manager. Their contact details are below. As always, you can contact them through the UKALL14 trial inbox at [ctc.ukall14@ucl.ac.uk](mailto:ctc.ukall14@ucl.ac.uk).

Trial Coordinator

Kalam Hussain Tel: 02076799169

Data Manager

Tanya-Louise Martin Tel: 02076799544

Latest contact details for the UKALL14 CTC trial team can be found in the CTC Contact List v10.

### Chimerism Reports

In addition to the main study, a paper is being written in relation to patients who have RIC-SCT. As part of this research, we are requesting multilineage chimerism data on RIC-SCT patients at 3 monthly intervals until 2 years post transplant. We would like percentage of donor cells in T cells, myeloid cells and whole blood.

Requests for reports have been sent to sites from the UKALL14 team. We would like to thank sites for the reports sent in and their help so far. If your site has not had a chance to send in the reports so far, we would very much appreciate it if reports could be sent in by 30th January 2020.

If you have any questions, please feel free to contact a member of the UKALL14 team.



### Other Trials

#### UKALL15

The UKALL15 trial will follow on from UKALL14. The trial will be submitted for funding in 2020. We hope that your site will participate in the trial.

#### ALL-RIC

We would like to invite sites to consider patients for the ALL-RIC study. ALL-RIC is a phase 2 study in adult patients with ALL in complete remission undergoing an allogeneic stem cell transplant comparing a novel conditioning regimen of TBI and cyclophosphamide with the standard condition regimen.

More information can be found on: <https://www.impactpartnership.org.uk/the-trials/all-ric/>



<u>Current Documentation</u>	<u>Version &amp; Date</u>	<u>Current Documentation</u>	<u>Version &amp; Date</u>
Protocol	v12.0 26/08/2018	Drug Supply Guidelines	v4 12/03/2018
PIS (registration only)	v3 28/06/2018	Investigator Site File Checklist	V16 09/12/2019
PIS (buccal swab)	v1 09/09/2015		